Clinical Trial Update: Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 pharmacodynamic study of subcutaneous goserelin 3.6 mg in premenopausal breast cancer patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• goserelin 3.6 mg injection (goserelin)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED